Log In
BCIQ
Print this Print this
 

Azarga, brinzolamide/timolol

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionEye drop combining brinzolamide, a carbonic anhydrase II (CA II) inhibitor, and timolol, a non-selective adrenoceptor beta1 and beta2 antagonist
Molecular Target Carbonic anhydrase II (CAII)
Mechanism of ActionCarbonic anhydrase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard Indication Ophthalmic (unspecified)
Indication DetailsReduce intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today